Ticker LaunchReverse merger · Completed · JBIO
Jade Biosciences
Reverse merger with Aerovate Therapeutics, Inc. (AVTE)
Jade Biosciences merged into Aerovate Therapeutics, Inc. (AVTE), a Nasdaq-listed clinical-stage biotech that distributed a special cash dividend before the merger, in a reverse merger that takes the private company public. The deal was announced on Oct 31, 2024 and closed on Apr 28, 2025. The combined company trades as Jade Biosciences, Inc. (JBIO) on Nasdaq.
Jade Biosciences, Inc. develops antibody therapies for autoimmune diseases, with lead candidate JADE-001 expected to enter the clinic in the second half of 2025 and two preclinical discovery programs.
- Status
- Completed
- Private company
- Jade Biosciences
- Public company
- Aerovate Therapeutics, Inc. (AVTE)
- Public company business before
- Nasdaq-listed clinical-stage biotech that distributed a special cash dividend before the merger
- Announced
- Oct 31, 2024
- Closed
- Apr 28, 2025
- Combined company
- Jade Biosciences, Inc. (JBIO)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K May 1, 2025
- Closing exhibit
- Announcement 8-K Oct 31, 2024
- Announcement exhibit
- All filings on EDGAR CIK 1798749
Other completed reverse mergers
- Crescent Biopharma, Inc.into GlycoMimetics, Inc. · Jun 13, 2025
- SRx Health Solutions, Inc.into Better Choice Company, Inc. · Apr 24, 2025
- METech Recycling, Inc.into First America Resources Corp · Apr 21, 2025
- Tvardi Therapeutics, Inc.into Cara Therapeutics, Inc. · Apr 15, 2025
- Synthesis Analytics Production Ltdinto Edgemode, Inc. · Apr 7, 2025
- Kalaris Tx, Inc.into AlloVir, Inc. · Mar 18, 2025